The aim of this study was to evaluate the toxicity and efficacy of a monochemotherapy
regimen of dacarbazine (DTIC), tamoxifen, interferon-α2a and interleukin-2 (IL-2) and two …

PURPOSE: The combination of chemotherapy with immunotherapeutic agents such as
interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results …

Background Based on phase II trial results, chemoimmunotherapy combinations have
become the preferred treatment for patients with metastatic melanoma in many institutions …

PURPOSE To evaluate the activity and the toxicity of the combination of cisplatin
(CDDP)/recombinant interleukin-2 (rIL-2) and interferon alfa-2a (IFN alpha) in disseminated …

We aimed to evaluate a concurrent chemobiotherapy (CBT) regimen consisting of cisplatin
(CDDP), dacarbazine (DTIC), decrescendo interleukin-2 (IL-2), and interferon α2b (INF-α2b) …

Aims and Background This trial evaluated the feasibility and tol-erability of an
immunochemotherapeutic approach that uses cisplatin, vindesine, and dacarbazine (DTIC) …

The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

Both chemotherapy and interleukin-2 and/or interferon-α produce objective responses in a
proportion of advanced malignant melanoma patients. While duration of response to …

The addition of cytokines, such as interferon α-2b and interleukin-2, to chemotherapy in
metastatic melanoma has produced conflicting results in phase II and III trials. We report our …

Background Metastatic melanoma is commonly treated with chemotherapy and/or biological
agents used separately. In this study we have investigated the efficacy of combined …